- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03417583
Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients
Phase A: Recruit 50 patients with HD, and their caregivers, to complete a neuropsychiatric and quality of life battery of scales at baseline. Have these 50 patients complete a formal psychiatric assessment with a psychiatrist within 2 weeks of this clinical battery, and the results of these 2 types of assessments will be compared to establish the level of agreement between clinical rating scales and formal psychiatric assessment.
Phase B: Continue to follow Phase A cohort longitudinally and administer neuropsychiatric and quality of life battery at 6 months, 12 months, and 18 months form baseline. Recruit an additional 50 patients, administer the same neuropsychiatric and quality of life battery at baseline, implement medication and counseling intervention according to a standard of care protocol, and follow up with the same neuropsychiatric and quality of life battery at 6, 12, and 18 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
As presented to Phase A (control) patient participant:
"If you are in this study, you will be asked to answer a series of online surveys assessing your psychiatric symptoms and quality of life in the presence of a caregiver. These surveys will be emailed to your consented caregiver in the week before your in-person visit. You will then come to clinic for an in-person assessment of psychiatric and motor symptoms of HD. You will also undergo an in-person psychiatric evaluation with a psychiatrist at Vanderbilt who works with HD patients. This psychiatric evaluation will take approximately 60 minutes and will occur up to 2 weeks before or after your first regular study visit. This involves a clinical interview during which a psychiatrist, who is an expert in psychiatric symptoms of HD, will ask about your experience with many different symptoms that can be experienced in HD. These two in-person evaluations will occur within 2 weeks of each other. You will continue to see your neurology provider for routine follow-up, and you will return for in-person follow-up assessments at 6 months, 12 months, and 18 months, repeating the online surveys prior to each visit.
Health-Related Quality of Life and Psychiatric Symptom Surveys (This will take approximately 60-90 minutes):
You will be asked to answer on-line survey questions about your psychiatric symptoms and quality of life in the presence of a caregiver.
- The Neuro-QoL scales include 4 subscales created specifically to measure quality of life in patients with neurological disease. These scales include 33 total questions which ask you to report your anxiety, depression, sense of well-being, and satisfaction with social roles within the previous week.
- The PROMIS Anger scale includes 8 questions that ask you to rate your symptoms of anger in the previous week.
- The PROMIS Sleep-Related Impairment short form includes 8 questions that ask about your sleep quality and how you feel during the day after sleeping.
- The Patient Health Questionnaire- 9 (PHQ-9) includes 9 questions about symptoms of depression that you may be experiencing and how these affect you on a daily basis.
- The HD Anosognosia Rating Scale includes 8 questions that ask you to assess how you perform daily tasks compared to other people of your same age and education level.
- Sleep Questionnaire includes 5 questions about your night and daytime sleep habits.
- We will also gather background information such as: date of birth, where you live, if you have insurance, and your income. You will also be asked about health and medical history such as: when you were diagnosed with HD and what medications you are taking.
Psychiatric and Motor Symptom Assessment (This will take approximately 60 minutes):
- The Hamilton Anxiety Rating Scale (HAM-A) asks you to rate the severity of 14 anxiety symptoms.
- The Problem Behaviors Assessment short form (PBA-s) asks you and your caregiver about the frequency and severity of 11 different psychiatric symptoms that can be experienced in HD.
- The Columbia Suicide Severity Rating Scale includes up to 6 items yes or no questions to assess presence and severity of suicidal thoughts.
- The Montreal Cognitive Assessment (MOCA) is short test to measure your memory and thinking skills.
- The United Huntington's Disease Rating Scale (UHDRS) tool is used by HD clinicians to measure the presence and severity of your motor symptoms like chorea and walking difficulty.
- The UHDRS Total Functional Capacity (TFC) scale is used by HD clinicians to rate your ability to carry out daily tasks such as household chores or managing finances."
As presented to Phase B (protocol) patient participant:
"If you are in this study, you will be asked to answer a series of online surveys assessing your psychiatric symptoms and quality of life in the presence of a caregiver. These surveys will be emailed to your consented caregiver in the week before your in-person visit. You will then come to clinic for an in-person assessment of psychiatric and motor symptoms of HD. In addition, your psychiatric symptoms will be treated according to a systematic protocol developed by HD experts that guides treatment decisions based on our current clinical standard of care. You will return for in-person follow-up assessment at 6 months, 12 months, and 18 months, repeating the online surveys prior to each visit.
Health-Related Quality of Life and Psychiatric Symptom Surveys (This will take approximately 60-90 minutes):
You will be asked to answer on-line survey questions about your psychiatric symptoms and quality of life in the presence of a caregiver.
- The Neuro-QoL scales include 4 subscales created specifically to measure quality of life in patients with neurological disease. These scales include 33 total questions which ask you to report your anxiety, depression, sense of well-being, and satisfaction with social roles within the previous week.
- The PROMIS Anger scale includes 8 questions that ask you to rate your symptoms of anger in the previous week.
- The PROMIS Sleep-Related Impairment short form includes 8 questions that ask about your sleep quality and how you feel during the day after sleeping.
- The Patient Health Questionnaire- 9 (PHQ-9) includes 9 questions about symptoms of depression that you may be experiencing and how these affect you on a daily basis.
- The HD Anosognosia Rating Scale includes 8 questions that ask you to assess how you perform daily tasks compared to other people of your same age and education level.
- Sleep Questionnaire includes 5 questions about your night and daytime sleep habits.
- We will also gather background information such as: date of birth, where you live, if you have insurance, and your income. You will also be asked about health and medical history such as: when you were diagnosed with HD and what medications you are taking.
Psychiatric and Motor Symptom Assessment (This will take approximately 60 minutes):
- The Hamilton Anxiety Rating Scale (HAM-A) asks you to rate the severity of 14 anxiety symptoms.
- The Problem Behaviors Assessment short form (PBA-s) asks you and your caregiver about the frequency and severity of 11 different psychiatric symptoms that can be experienced in HD.
- The Columbia Suicide Severity Rating Scale includes up to 6 items yes or no questions to assess presence and severity of suicidal thoughts.
- The Montreal Cognitive Assessment (MOCA) is short test to measure your memory and thinking skills.
- The United Huntington's Disease Rating Scale (UHDRS) tool is used by HD clinicians to measure the presence and severity of your motor symptoms like chorea and walking difficulty.
- The UHDRS Total Functional Capacity (TFC) scale is used by HD clinicians to rate your ability to carry out daily tasks such as household chores or managing finances."
As presented to caregiver participant:
"If you are involved in this study, you will be asked to assist the HD patient in completing a series of online surveys assessing his or her psychiatric symptoms and quality of life. You will also be asked to complete an online survey about your experience as a caregiver:
• The Traumatic Brain Injury- Care Quality of Life (TBI-CareQOL) Caregiver Strain short form includes 6 items which ask you to rate your feelings of stress and strain related to being a caregiver.
All surveys will be emailed to you the week prior to an in-person study visit.
You will then accompany the HD patient to clinic for an in-person assessment of psychiatric and motor symptoms of HD. During this visit you will be asked to answer questions about the patient's psychiatric symptoms (see scales below) and offer input on other symptom surveys directed to the patient as you would in a normal clinic visit.
- The Factor analysis of the frontal systems behavior scale (FrSBe) family-version is a 46-item scale that asks you to rate characteristics of frontal lobe dysfunction that you observe in the HD patient currently and prior to disease onset.
- The Problem Behaviors Assessment short form (PBA-s) asks you and the HD patient about the frequency and severity of 11 different psychiatric symptoms that can be experienced in HD. "
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jennifer Hoadley
- Phone Number: 615-875-1257
- Email: jennifer.hoadley@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patient participants:
- Diagnosed with HD, either through genetic testing or neurologist's clinical diagnosis
- Patient has at least 1 neuropsychiatric symptom, as reported by their HD provider
- 21 and older will be included, as symptoms of Juvenile HD (in patients 20 years old or less) can present differently
- Presence of an eligible caregiver who can also participate in the study with them because several of the study measures require caregiver report
Caregivers:
- 18 years or older
- A caregiver will be defined as someone who lives with or has at least weekly contact with the HD patient
Exclusion Criteria:
Patient participants:
- 20 years old or younger
- Greater than moderate impairment on dementia screening
- Lack of a caregiver to provide collateral information and complete caregiver assessments will also be excluded
Caregivers:
- Younger than 18 years old and/or have less than weekly contact with the HD patient
- Clinical impression of incompetency to answer survey questions as determined by the Jessie Sellers, Nurse Practitioner, or the neurologist caring for the HD patient, then he or she will not be eligible to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Clinical Standard Care Group
These patients will continue to be seen by their regular neurology provider for Huntington's disease.
They will not be treated explicitly according to the protocol, though they may be prescribed some of the same medications.
|
|
Experimental: Protocol Intervention Group
These participants will transfer their clinical care to the study provider for the duration of the study, and their symptom treatment will be guided by the study protocol.
|
For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented.
This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction.
These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in quality of life- Concern with Death and Dying
Time Frame: Baseline to 18 months
|
This is measured using the HDQLIFE Concern with Death and Dying scale, which measures concern with death and dying in Huntington's disease patients.
The total score will range from 6 to 30, with higher scores indicating greater concern with death and dying.
|
Baseline to 18 months
|
Change in quality of life- Meaning and Purpose
Time Frame: Baseline to 18 months
|
This is measured using HDQLIFE Meaning and Purpose scale, which measures feelings of meaning and purpose in Huntington's disease patients.
The total score will range from 4 to 20, with higher scores indicating greater feelings of meaning and purpose in life.
|
Baseline to 18 months
|
Change in quality of life- Ability to Participate in Social Roles and Activities
Time Frame: Baseline to 18 months
|
This is measured using the NeuroQoL- Ability to Participate in Social Roles and Activities scale, which measures ability of individuals with neurological conditions to participate in social roles and activities.
The total score will range from 8 to 40, with higher scores indicating greater ability to participate in social roles and activities.
|
Baseline to 18 months
|
Change in quality of life- Anxiety
Time Frame: Baseline to 18 months
|
This is measured using the NeuroQoL- Anxiety scale, which measures anxiety in individuals with neurological conditions.
The total score will range from 8 to 40, with higher scores indicating greater levels of anxiety.
|
Baseline to 18 months
|
Change in quality of life- Depression
Time Frame: Baseline to 18 months
|
This is measured using the NeuroQoL- Depression scale, which measures depression in individuals with neurological conditions.
The total score will range from 8 to 40, with higher scores indicating greater levels of depression.
|
Baseline to 18 months
|
Change in quality of life- Positive Affect and Well-Being
Time Frame: Baseline to 18 months
|
This is measured using the NeuroQoL- Positive Affect and Well-Being scale, which measures positive affect and sense of well-being in individuals with neurological conditions.
The total score will range from 9 to 45, with higher scores indicating a greater sense of well-being.
|
Baseline to 18 months
|
Change in quality of life- Satisfaction with Social Roles and Activities
Time Frame: Baseline to 18 months
|
This is measured using the NeuroQoL- Satisfaction with Social Roles and Activities scale, which measures satisfaction with social roles and activities in individuals with neurological conditions.
The total score will range from 8 to 40, with higher scores indicating greater levels of satisfaction with social roles and activities.
|
Baseline to 18 months
|
Change in quality of life- Caregiver Strain
Time Frame: Baseline to 18 months
|
This is measured using the TBI-CareQoL- Caregiver Strain scale, which measures health related quality of life in caregivers.
The total score will range from 6 to 30, with higher scores indicating greater levels of caregiver strain.
|
Baseline to 18 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: David Isaacs, Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Heredodegenerative Disorders, Nervous System
- Dementia
- Cognition Disorders
- Chorea
- Huntington Disease
Other Study ID Numbers
- 172030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Huntington Disease
-
University of IowaThe University of Texas Health Science Center, Houston; Children's Hospital... and other collaboratorsRecruitingJuvenile Huntington Disease | Juvenile-Onset Huntington DiseaseUnited States
-
Sanguine BiosciencesHoffmann-La RocheRecruitingHuntington Disease | Huntington's Dementia | Huntington Disease, Late Onset | Huntington; Dementia (Etiology)United States
-
PrileniaCompletedHealth Volunteers, Huntington DiseaseGermany
-
Assistance Publique - Hôpitaux de ParisCEACompletedBrain Neuroimaging Biomarkers in Huntington DiseaseFrance
-
European Huntington's Disease NetworkCompletedHuntington Disease, JuvenileGermany, United Kingdom
-
Novartis PharmaceuticalsCompletedEarly Manifest Huntington DiseaseCanada, Germany, France, Spain, Hungary
-
University Hospital, AngersCompletedPresymptomatic Huntington DiseaseFrance
-
SOM Innovation Biotech SAActive, not recruitingHuntington ChoreaSpain, Germany, Italy, United Kingdom, France, Poland, Switzerland
-
Neurocrine BiosciencesEnrolling by invitation
-
Neurocrine BiosciencesHuntington Study GroupActive, not recruitingChorea, HuntingtonUnited States, Canada
Clinical Trials on Protocol Intervention Group
-
Texas A&M UniversityAmerican Psychological Foundation; Psi Chi; Academy for Eating DisordersCompletedBinge EatingUnited States
-
Viviane de Souza Pinho CostaCompletedVestibular Diseases
-
Huazhong University of Science and TechnologyWuhan Union Hospital, China; Wuhan No.1 Hospital; The Affiliated Hospital of... and other collaboratorsRecruitingDiminished Ovarian ReserveChina
-
University of Sao Paulo General HospitalCompleted
-
Hacettepe UniversityRecruitingRotator Cuff Injuries | Rotator Cuff Tears | Pain, ShoulderTurkey
-
Cairo UniversityJouf UniversityCompleted
-
Professor Fernando Figueira Integral Medicine InstituteCompletedQuality of Life | Breast Cancer | Physical Activity | Physical Fitness
-
University Hospital, BordeauxInstitut National de la Santé Et de la Recherche Médicale, France; Université... and other collaboratorsCompletedAlzheimer's DiseaseFrance
-
Instituto Docusse de Osteopatia e Terapia ManualCompleted
-
University of Sao PauloSociedade Hospital SamaritanoCompletedQuality of Life | StressBrazil